FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for differential diagnosis of ascitic-infiltrative form of ovarian cancer and abdominal tuberculosis. Method includes, in an ascitic fluid, determining level of marker HE4, if its value is 244.1 ± 22.7 pmol/l, ascitic-infiltrative form of ovarian cancer, and if value is 43.5 ± 4.8 pmol/l, abdominal tuberculosis.
EFFECT: method improves results of differential diagnosis of ovarian cancer of ascitic-infiltrative form and abdominal tuberculosis.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF OVARIAN CANCER PERITONEAL PROPAGATION | 2019 |
|
RU2722654C1 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD FOR DETERMINING THE EFFECTIVENESS OF CHEMOTHERAPY WITH PLATINUM PREPARATIONS IN III-IV STAGE OVARIAN CANCER | 2020 |
|
RU2738167C1 |
| METHOD FOR PREDICTION OF PROBABILITY OF POSSIBLE EXECUTION OF OPTIMUM CYTOREDUCTIVE OPERATION IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637399C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT NEOPLASMS OF OVARIES | 2018 |
|
RU2686180C1 |
| METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
| METHOD FOR PREDICTION OF RISK OF TUMOUR PROGRESSION IN PATIENTS WITH OVARIAN CANCER | 2023 |
|
RU2816339C1 |
| METHOD FOR MODELING OVARIAN CANCER EXPERIMENTALLY IN RATS | 2020 |
|
RU2743219C1 |
| METHOD OF PREDICTING EFFICIENCY OF ANTITUMOUR TREATMENT | 2009 |
|
RU2411913C1 |
| METHOD OF DETERMINING DURATION OF RECURRENCE-FREE INTERVAL IN SEROUS OVARIAN CANCER | 2015 |
|
RU2613302C1 |
